Kompleks polimaltozy z wodorotlenkiem żelaza w leczeniu niedoboru żelaza i niedokrwistości z niedoboru żelaza w okresie ciąży

Introduction. Iron deficiency (ID), and iron deficiency anaemia (IDA) are consistently associated with reduced maternal cognitive function and increased depressive disorders. In addition, the preterm delivery, and intra-uterine growth restriction were reported as an adverse neonatal outcome for ID and IDA. This study designed to evaluate the efficacy of ferric hydroxide polymaltose (FPM) in treatment of ID, and IDA during pregnancy. Materials and methods . One hundred and twenty-two women with ID (ferritin < 15 μg/L), and moderate IDA (haemoglobin ≥ 7 and < 10 g/dL) during pregnancy were included in this study. Studied women treated with FPM tablets for ≥ 3 months. The pre-treatment ferritin, haemoglobin, red blood cells (RBCs)-mean corpuscular volume (MCV), and -mean corpuscular haemoglobin (MCH) were compared by post-treatment values. Results. The mean pre-treatment ferritin, and haemoglobin significantly increased from 12.4 ± 5.6 μg/L and 7.8 ± 3.3 g/dL; respectively to 116.5 ± 6.9 μg/L and 11.1 ± 2.8 g/dL; respectively, 3-months’ after FPM treatment (p = 0.02 and 0.0002; respectively). In addition, the mean pretreatment RBCs MCV, and MCH significantly increased from 73.5 ± 4.6 fL and 24.2 ± 7.7 pg; respectively to 94.0 ± 3.8 fL and 31.7 ± 6.3 pg; respectively 3-months’ after FPM treatment (p = 0.02 and 0.01; respectively). Conclusion. The FPM (Ferose ® ) is an effective therapeutic option for treatment of ID, and IDA during pregnancy with high safety profile, and low side effects. The superior tolerability of FPM is an important advantage because compliance to oral iron is the main obstacle toward effective treatment of ID, and IDA during pregnancy.